Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 1, 2008, Pages 3-13

  Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Insulin; Metformin; Sulfonylurea; Thiazolidinediones

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLITAZONE DERIVATIVE; INCRETIN; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ADJUVANT THERAPY; BLOATING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; FLATULENCE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MEDLINE; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN ALLERGY; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 38749103090     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.783     Document Type: Review

References (87)

1. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
2. Ponssen HH, Elte JW, Lehert P, Schouten JP, Bets D. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.Clin Ther 2000; 22: 709-718.
3. American Diabetes Association Position Statement. Standards of medical care in diabetes-2007. Diabetes Care 2007; 30: S4-S41.
4. ACE/AACE Position Statement. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006; 12: 6-12.
5. Monnier L, Grimaldi A, Charbonnel B, et al. Management of French patients with type 2 diabetes in medical general practice: Report of the Mediab observatory. Diabet Met 2004; 30: 35-42.
6. Nelson SE, Palumbo PJ. Addition of insulin to oral therapy in patients with type 2 diabetes. Am J Med Sci 2006; 331: 257-263.
7. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182-188.
8. Hirsch B. Metformin added to insulin therapy in poorly controlled type 2 diabetes. Diabetes Care 1999; 22: 854.
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
10. Deeg MA. Basic approach to managing hyperglycemia for the nonendocrinologist. Am J Cardiol 2005; 96: 37E-40E.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
12. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab 2006; 8: 39-48.
13. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebocontrolled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.
14. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002; 25: 1691-1698.
15. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, doubleblind, prospective, multicenter, parallel-group study. Clin Ther 2005; 27: 554-567.
16. Charbonnel B, Dormandy J, Erdman E, Massi-Benedetti M, Skene A, PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: l647-1653.
17. Sarafidis P, Nilsson P. The effects of thiazolidinediones on blood pressure levels-a systematic review. Blood Press 2006; 15: 135-150.
18. Heine R, Schindhelm R, Diamant M. Long-term pioglitazone treatment improves markers of liver function: results from PROactive. Abstract 484-P. Presented at the 66th Annual Scientific Sessions of the American Diabetes Association, Washington, DC, 11 June 2006.
19. Huang A, Raskin P. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Treat Endocrinol 2005; 4: 205-220.
20. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological trearment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-2803.
21. Esposito K, Giugliano D, Nappo F, Marfella R, Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219.
22. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
23. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
24. Doggrell SA. Recent evidence of sustained benefit with exenatide in Type 2 diabetes. Expert Opin Pharmacother 2006; 7: 2003-2006,
25. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on AlC, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447.
26. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
27. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 2003; 5: 408-414.
28. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26: 784-790.
29. Josse RG, Chiasson JL, Ryan EA, et al. Acarbose in the treatment of elderly persons with type 2 diabetes. Diabetes Res Clin Pract 2003; 59: 37-42.
30. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49: 434-441.
31. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Pbysician 2004; 70: 489-500.
32. Choi YH, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin. Br J Pharmacol 2006; 149: 424-430.
33. Scheen AJ, Lefebvre PJ. Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients. Rev Med Liege 2005; 60: 896-901.
34. Hermann LS. Gombination therapy with insulin and metformin. Endocr Pract 1998; 4: 404-412.
35. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A Randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 176-185.
36. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.
37. Buch HN, Baskar V, Barton DM, Kamalakannan D, Akarca C, Singh BM. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. Diabet Med 2002; 19: 572-574.
38. Pfutzner A, Schneider GA, Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 2006; 4: 445-459.
39. Wilcox R, Kupfer S. Effects of pioglitazone on major adverse cardiovascular events (MACE) and myocardial infarction: results from PROactive. Abstract 317-0R. Presented at the 66th Annual Scientific Sessions of the American Diabetes Association, 12 June 2006; Washington, DC.
40. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
41. Scheen AJ, Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: Results from PROactive. Diabetes 2006; 55(Suppl 1): A134 (Abstract 561-P).
42. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
43. Fuster V, Farkouh ME. Faster publication isn't always better. Nat Clin Pract Cardiovasc Med 2007; 4: 345.
44. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28-38.
45. Consoli A, Devangelio E. Thiazolidinediones and inflammation. Lupus 2005; 14: 794-797.
46. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24: 392-397.
47. Goval A, Crook ED. Thiazolidinediones and progression of renal disease in patients with diabetes. J Investig Med 2006; 54: 56-61.
48. Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004; 27: 841-856.
49. Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 2005; 7: 633-641.
50. Avandia (rosiglitazone maleate) tablets [prescribing information]. Research Triangle Park, NC, GlaxoSmithKline, August 2007. Available at http://us.gsk.com/products/assets/us_avandia.pdf. Assessed 25 September 2007.
51. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
52. U.S. Food and Drug Administration. 2007; Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. Actos. March 9, 2007. Available at http://www.fda.gov/medwatch/safety/2007/ safety07.htm#actos, (accessed July 10, 20O7).
53. U.S. Food and Drug Administration. 2007; Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. Avandia. February 20, 2007. Available at http://www.fda.gov/medwatch/safety/2007/ safety07.htm# rosiglitazone (accessed July 10, 2007).
54. Schwartz AV, Sellmeyer DE. Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 2007; 30: 1670-1671.
55. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005; 28: 601-631.
56. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18(Suppl 2): 23-29.
57. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003; 26: 3273-3279.
58. Raskin P, Rogelio B, Schwartz S, Chaykin L, Chu P, Wynne A. Over 75% of patients with type 2 diabetes reached target AlC by adding biphasic insulin aspart 70/30 to optimized metformin and pioglitazone treatment. Diabetes 2006; 55(Suppl 1): A131 (Abstract 549-P).
59. Strowig SM, Aviles-Santa ML, Raskin P. lmproved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 2004; 27: 1577-1583.
60. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A metalanalysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-264.
61. Kyllastinen M, Groop L. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Ann Clin Res 1985; 17: 100-104.
62. Simpson HC, Sturley R, Stirling CA, Reckless JP. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients. Diabet Med 1990; 7: 143-147.
63. Standl E, Maxeiner S, Raptis S, HOE901/4009 Study Group. Once daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment fiexibility. Horm Metab Res 2006; 38: 172-177.
64. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998; 21: 1052-1057.
65. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992; 15: 953-959.
66. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006; 55(Suppl 1): 2-5.
67. Casner PR. Insulin-glyburide combination therapy for noninsulin-dependent diabetes mellitus: a long-term doubleblind, placebo-controlled trial. Clin Pharmacol Ther 1988; 44: 594-603.
68. Groop L, Harno K, Nikkila EA, Pelkonen R, Tolppanen EM. Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. Acta Med Scand 1985; 217: 33-39.
69. Feinglos MN, Thacker CR, Lobaugh B, et al. Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 39: 193-199.
70. Green JB, Feinglos MN. Are sulfonylureas passe? Curr Diab Rep 2006; 6: 373-377.
71. Thisted H, Johnson SP, Runby J. Sulfonylureas and the risk of myocardial infarction. Metab Clin Exp 2006; 55(Suppl 1): S16-S19.
72. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y. Druginduced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 1999; 159: 281-284.
73. Chang JH, Tseng CF, Wang JY. Hypoglycemia-induced myocardial infarction: an unusual adverse effect of sulfonylureas. Int J Cardiol 2007; 115: 414-416, (Epub 2006 Jun 19).
74. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26: 1485-1489.
75. Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005; 60: 103-106.
76. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metab Clin Exp 2006; 55(Suppl 1): 20-27.
77. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991; 115: 45-53.
78. Malaisse WJ. Pharmacology of the meglitinide analogs. New treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003; 2 401-414.
79. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
80. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treatto-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
81. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.
82. Rolla AR, Rakel BE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005; 27: 1113-1125.
83. Polansky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
84. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
85. Liebl A, Prager R, Kaiser M, Binz K, Gallwitz B. Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach AlC target: the PREFER study. Diabetes 2006; 55(Suppl 1): A123.
86. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
87. Malone JK, Kerr LF, Campaigne BN, 8achson RA, Holcombe JH, Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044.